BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 24195603)

  • 1. Biosafety challenges for use of lentiviral vectors in gene therapy.
    Rothe M; Modlich U; Schambach A
    Curr Gene Ther; 2013 Dec; 13(6):453-68. PubMed ID: 24195603
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Gene therapy using retrovirus vectors: vector development and biosafety at clinical trials].
    Doi K; Takeuchi Y
    Uirusu; 2015; 65(1):27-36. PubMed ID: 26923955
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insertional gene activation by lentiviral and gammaretroviral vectors.
    Bokhoven M; Stephen SL; Knight S; Gevers EF; Robinson IC; Takeuchi Y; Collins MK
    J Virol; 2009 Jan; 83(1):283-94. PubMed ID: 18945765
    [TBL] [Abstract][Full Text] [Related]  

  • 4. State-of-the-art lentiviral vectors for research use: risk assessment and biosafety recommendations.
    Pauwels K; Gijsbers R; Toelen J; Schambach A; Willard-Gallo K; Verheust C; Debyser Z; Herman P
    Curr Gene Ther; 2009 Dec; 9(6):459-74. PubMed ID: 20021330
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biosafety considerations using gamma-retroviral vectors in gene therapy.
    Deichmann A; Schmidt M
    Curr Gene Ther; 2013 Dec; 13(6):469-77. PubMed ID: 24195605
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trial watch: Clinical trial boost for lentiviral gene therapy.
    Flight MH
    Nat Rev Drug Discov; 2013 Sep; 12(9):654. PubMed ID: 23989781
    [No Abstract]   [Full Text] [Related]  

  • 7. Safer, silencing-resistant lentiviral vectors: optimization of the ubiquitous chromatin-opening element through elimination of aberrant splicing.
    Knight S; Zhang F; Mueller-Kuller U; Bokhoven M; Gupta A; Broughton T; Sha S; Antoniou MN; Brendel C; Grez M; Thrasher AJ; Collins M; Takeuchi Y
    J Virol; 2012 Sep; 86(17):9088-95. PubMed ID: 22696657
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biosafety features of lentiviral vectors.
    Schambach A; Zychlinski D; Ehrnstroem B; Baum C
    Hum Gene Ther; 2013 Feb; 24(2):132-42. PubMed ID: 23311447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimization of lentiviral vectors generation for biomedical and clinical research purposes: contemporary trends in technology development and applications.
    Kumar P; Woon-Khiong C
    Curr Gene Ther; 2011 Apr; 11(2):144-53. PubMed ID: 21291355
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene delivery by lentivirus vectors.
    Cockrell AS; Kafri T
    Mol Biotechnol; 2007 Jul; 36(3):184-204. PubMed ID: 17873406
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biosafety of lentiviral vectors.
    Debyser Z
    Curr Gene Ther; 2003 Dec; 3(6):517-25. PubMed ID: 14683448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biosafety of recombinant adeno-associated virus vectors.
    Dismuke DJ; Tenenbaum L; Samulski RJ
    Curr Gene Ther; 2013 Dec; 13(6):434-52. PubMed ID: 24195602
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of the internal promoter on insertional gene activation by lentiviral vectors with an intact HIV long terminal repeat.
    Knight S; Bokhoven M; Collins M; Takeuchi Y
    J Virol; 2010 May; 84(9):4856-9. PubMed ID: 20181689
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gene Therapy in Fanconi Anemia: A Matter of Time, Safety and Gene Transfer Tool Efficiency.
    Verhoeyen E; Roman-Rodriguez FJ; Cosset FL; Levy C; Rio P
    Curr Gene Ther; 2017; 16(5):297-308. PubMed ID: 28067165
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ten years of gene therapy for primary immune deficiencies.
    Aiuti A; Roncarolo MG
    Hematology Am Soc Hematol Educ Program; 2009; ():682-9. PubMed ID: 20008254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Uncovering and dissecting the genotoxicity of self-inactivating lentiviral vectors in vivo.
    Cesana D; Ranzani M; Volpin M; Bartholomae C; Duros C; Artus A; Merella S; Benedicenti F; Sergi Sergi L; Sanvito F; Brombin C; Nonis A; Serio CD; Doglioni C; von Kalle C; Schmidt M; Cohen-Haguenauer O; Naldini L; Montini E
    Mol Ther; 2014 Apr; 22(4):774-85. PubMed ID: 24441399
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Viral Vectors: The Road to Reducing Genotoxicity.
    David RM; Doherty AT
    Toxicol Sci; 2017 Feb; 155(2):315-325. PubMed ID: 27803388
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel bovine lentiviral vectors based on Jembrana disease virus.
    Metharom P; Takyar S; Xia HH; Ellem KA; Macmillan J; Shepherd RW; Wilcox GE; Wei MQ
    J Gene Med; 2000; 2(3):176-85. PubMed ID: 10894263
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lentiviral haemopoietic stem/progenitor cell gene therapy for treatment of Wiskott-Aldrich syndrome: interim results of a non-randomised, open-label, phase 1/2 clinical study.
    Ferrua F; Cicalese MP; Galimberti S; Giannelli S; Dionisio F; Barzaghi F; Migliavacca M; Bernardo ME; Calbi V; Assanelli AA; Facchini M; Fossati C; Albertazzi E; Scaramuzza S; Brigida I; Scala S; Basso-Ricci L; Pajno R; Casiraghi M; Canarutto D; Salerio FA; Albert MH; Bartoli A; Wolf HM; Fiori R; Silvani P; Gattillo S; Villa A; Biasco L; Dott C; Culme-Seymour EJ; van Rossem K; Atkinson G; Valsecchi MG; Roncarolo MG; Ciceri F; Naldini L; Aiuti A
    Lancet Haematol; 2019 May; 6(5):e239-e253. PubMed ID: 30981783
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of gene therapy for hematopoietic stem cells using lentiviral vectors.
    Woods NB; Ooka A; Karlsson S
    Leukemia; 2002 Apr; 16(4):563-9. PubMed ID: 11960333
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.